Sanofi, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer
Date August 01, 2013
Sanofi brought the big pharma reporting season to an ignominious close today when it cut its guidance for the year and reported disappointing second-quarter figures. An embarrassing performance at its generics business in Brazil was largely to blame while patent losses and weak performances at several units also hit.
Sanofi’s setback – which sent the French drugmaker’s shares down 6.7% – stands out in a reporting season that has contained few big surprises. The patent cliff might be in the rear view mirror but several big pharma names are still dealing with generic erosion of huge products; elsewhere, the massive restructuring and cost containment programmes being implemented to preserve profit margins make for uneventful quarters. But Sanofi’s results, coming in the wake of Glaxo's troubles in China, show how emerging markets are becoming an ever more important influence on earnings, meaning investor scrutiny is only going to mount on these operations.
- Forums
- ASX - By Stock
- UNS
- sanofi have bad second quarter
sanofi have bad second quarter
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add UNS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online